Cancer Clinical Trials: Survival Used As Endpoint 12% Of Time, FDA Reports
Executive Summary
An FDA review of oncology drug approvals during the last eight years indicates that the survival endpoint has been used relatively infrequently to support a growing number of approved indications
You may also be interested in...
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31